(Q27004170)

A. Osterborg

2

1 reference

P. Gascon

3

1 reference

H. Ludwig

4

1 reference

Y. Beguin

5

1 reference

language of work or name

1 reference

August 2012

1 reference

1 reference

23

1 reference

PubMed

issue

8

1 reference

PubMed

page(s)

1954-62

1 reference

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Ferric carboxymaltose in patients with heart failure and iron deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Anaemia of cancer: an overview of mechanisms involved in its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Labile iron in parenteral iron formulations: a quantitative and comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Iron metabolism in the anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Anemia in oncology practice: relation to diseases and their therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Assessing iron status: beyond serum ferritin and transferrin saturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

The silent risks of blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Hypersensitivity reactions and deaths associated with intravenous iron preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Update on adverse drug events associated with parenteral iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Do two intravenous iron sucrose preparations have the same efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Role of iron in carcinogenesis: cancer as a ferrotoxic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS112

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS112

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22575608

1 reference

Consolidated OpenCitations Corpus – April 2017